Editor's note: An earlier version of this article incorrectly stated that Eli Lilly purchased two companies from Siemens. The actual transaction was for two tracers used in detecting tau tangles. The video also misidentifies a collaboration between Eli Lilly and General Electric for similar diagnostic products. GE Healthcare is developing a tau tangle imaging test that is independent of Eli Lilly. The Fool regrets the error.
In this video, health care analyst David Williamson discusses Eli Lilly's (NYSE:LLY) recent purchase of two imaging tracers from German conglomerate Siemens. The big pharma currently has Amyvid approved, which detects amyloid brain plaques. Like Amyvid, Eli Lilly is hoping that these tau tangle diagnostics will help both with detection and potentially serve as markers for treatment. Watch and find out how the treatment for Alzheimer's disease is evolving and some potentially groundbreaking drugs in the pipeline.
David Williamson has no position in any stocks mentioned. The Motley Fool owns shares of General Electric Company. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is Eli Lilly and Company a Buy in 2018?
The outlook is complicated for this big pharma stock.
Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc.
Find out which big American pharma is best suited to provide big gains in the years to come.